Results 151 to 160 of about 5,563 (240)

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract INTRODUCTION A subset of Alzheimer's disease (AD) patients exhibits a procoagulant state that remains undiagnosed despite available treatments. We developed positron emission tomography (PET) strategies to in vivo detect cerebral microthrombi in TgCRND8 mice. METHODS PET was performed with a fibrin‐binding probe (FBP) in TgCRND8 and wild‐type
Carlos Ceron, Marta Casquero‐Veiga, Nicolás Lamanna‐Rama, Irene Fernández‐Nueda, Alberto Fernández‐Pena, Nancy Olazagoitia, Gorka Sobrino, Aitor Herraiz, María Isabel González, María Muñoz‐Hernando, Alejandro Ruperti‐Repilado, Eduardo Romero‐Sanz, Miguel Ángel Morcillo, Carlos Pérez‐Medina, Maria Angeles Moro, Gonzalo Villaverde, Jorge Rubio, Jose Fernandez‐Ferro, Manuel Desco, Fernando Herranz, Beatriz Salinas, Valentin Fuster, Marta Cortes‐Canteli   +22 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, Volume 78, Issue 7, Page 1393-1402, July 2026.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2162-2170, July 2026.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. [PDF]

Front Immunol
Zou L, Chen J, Bai X, Wang Y, Lu C, Wang Q, Tuerhong S, Li M, Zheng Q, Meng F, Du J.   +10 more
europepmc   +2 more sources

Chemical‐Assembled Macrophage‐Engaging Glypican‐3 × Signal Regulatory Protein‐α (SIRP‐α) Bispecific Antibody for Immunotherapy Against Liver Cancer

MedComm, Volume 7, Issue 7, July 2026.
We developed a novel chemical strategy to generate a glypican‐3 × SIRP‐α bispecific antibody that simultaneously blocks the CD47 “don't eat me” signal, engages macrophages to target liver cancer cells for enhanced phagocytosis, and antigen presentation. This novel combination of targets demonstrates remarkable efficacy in vitro and in vivo.
Bo Tang, Wing Hei Leung, Chihao Shao, Dongfang Li, Kwai Man Lau, Macro K. H. Lui, Jingyi Liu, Jacky C. H. Chu, Clare S. W. Yan, Chi‐Ming Che, Xuechen Li, Wing‐Tak Wong, Larry Ming Cheung Chow, Terence K. W. Lee, Clarence T. T. Wong   +14 more
wiley   +1 more source

Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies

MedComm, Volume 7, Issue 7, July 2026.
This review illustrates the key mechanisms of osimertinib resistance in EGFR‑mutant NSCLC, including EGFR‑dependent mutations, bypass pathway activation, and SMARCA4‑mediated epigenetic regulation. We also summarize emerging targeted therapies and future perspectives to overcome EGFR‑TKI resistance.
Junfeng Guo, Qiuyuan Wen, Songqing Fan
wiley   +1 more source

Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report

Respirology Case Reports, Volume 14, Issue 7, July 2026.
We report a fatal case of acute TLS following a single 1‐mg dose of tarlatamab in a patient with relapsed SCLC with extensive liver metastases. This case highlights the importance of TLS risk assessment prior to tarlatamab treatment. Extensive liver metastases and elevated lactate dehydrogenase levels may be risk factors for TLS in patients with SCLC ...
Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue   +8 more
wiley   +1 more source

Clonal Hematopoiesis and Type 2 Diabetes: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
Clonal hematopoiesis (CH), driven by obesity‐ and aging‐related inflammation, may be causally associated with an increased risk of Type 2 diabetes through the inflammation–insulin resistance pathway. By exacerbating systemic inflammation, CH may also contribute to the development of macrovascular and microvascular complications in patients with Type 2 ...
Jian‐Jun Liu, Sylvia Liu, Resham L. Gurung, Su Chi Lim, Rajkumar Dorajoo   +4 more
wiley   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, Volume 117, Issue 1, Page 42-54, July 2026.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source